Ionis Beats EPS Forecast by $0.56 as Revenue Jumps 54.8%

Ionis Pharmaceuticals beat consensus expectations by $0.56 per share on Monday, reporting a loss of ($0.66) EPS for the quarter against the analyst estimate of ($1.22), according to Zacks. The company booked $242.72 million in revenue, exceeding the $181.57 million analysts had projected. Revenue rose 54.8% year over year. In the same quarter a year earlier, the company posted ($0.80) per share.

The headline numbers carry weight beyond a single quarter. They frame the question every finance desk is asking: can an RNA-targeted drug developer with deep losses sustain the trajectory its top line now shows?

What Do the Earnings Show?

The quarter's arithmetic is straightforward. A smaller-than-expected loss, driven by revenue that ran roughly 34% above the street's number, pushed shares of the Carlsbad, California-based biotech through a reporting cycle that many peers have fumbled. Profitability, though, remains distant. Ionis reported a negative net margin of 64.76% and a negative return on equity of 111.08%.

Those two figures tell the story of a company still spending heavily to convert its pipeline into commercial products. For now, the market rewards the revenue line.

How Has the Stock Traded?

Ionis stock opened at $39.42 on Monday. That price sits near the bottom of a wide range: a 12-month low of $38.31 and a 12-month high of $86.74.

The technical picture mirrors the fundamental one. Consider the balance-sheet and trading metrics:

• Market cap: $6.55 billion
• P/E ratio: -11.39
• Beta: 0.43
• Quick ratio: 7.73; current ratio: 7.89
• Debt-to-equity ratio: 3.07
• 50-day moving average: $46.80; 200-day average: $65.88

The stock trades well below both its 50-day and 200-day moving averages, a sign that Monday's beat landed after months of decline. The liquidity ratios, both near eight, signal a balance sheet with ample near-term cushion despite the equity losses. In plain terms: the company has cash and short-term assets to fund its operations, even as accounting profitability stays negative.

Who Sold Shares?

Executive Vice President Shannon Devers sold 1,357 shares on Friday, October 16, at an average price of $43.54, for a total of $59,083.78. The transaction cut the EVP's direct holding by 7.08%, to 17,811 shares valued at $775,490.94. The company disclosed the sale in an SEC filing.

The filing states the sale covered tax withholding obligations tied to the vesting of equity awards — a routine mechanical reason, not a vote of confidence either way. Insiders own 1.81% of the company's stock.

Where Do Analysts Stand?

The sell side has trimmed targets but kept its overall stance. The recent changes:

• Canaccord Genuity cut its price target from $95.00 to $85.00 on September 8, keeping a "buy" rating.
• Needham & Company reiterated a "buy" rating with an $86.00 target on September 4.
• Citigroup reissued a "buy" rating on October 21.
• Barclays lowered its target from $90.00 to $85.00 on September 9, with an "overweight" rating.
• Oppenheimer reiterated an "outperform" rating and an $85.00 target on September 24.

Across the coverage universe, 19 analysts rate the stock a Buy, three a Hold, and one a Sell. MarketBeat calculates a consensus rating of "Moderate Buy" with an average target price of $89.48 — more than double Monday's opening price.

The gap between the $89.48 consensus target and the $39.42 open is the widest signal in this story. Analysts either see a recovery the market has not priced, or their targets lag the stock's slide.

Why Does This Company Matter?

Ionis discovers and develops RNA-targeted medicines, focused on antisense oligonucleotides — synthetic strands designed to bind RNA and alter the production of proteins linked to disease. Its research programs span neurological, cardiovascular, metabolic and rare diseases.

The company commercializes some medicines itself and advances others with pharmaceutical partners. Its treatments and partnered products address conditions including spinal muscular atrophy and transthyretin amyloidosis.

The takeaway for finance teams: Ionis beat on both lines of the income statement, holds a liquid balance sheet, and trades at less than half the analysts' average target — while still losing roughly 65 cents of every revenue dollar. The next quarter's margin will matter more than this one's beat.